GlassScriptPhysician profile
Vincent B Robinson
NPI 1851401848
$1,613.66
in general payments reported to CMS, 2019-2025
24 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $57.45 · 2021: $207 · 2022: $165 · 2023: $278 · 2024: $200 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914 · Education: $60.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $914.35 |
| Education | $60.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $179.94 | 2019-2025 | |
| Pfizer INC. | $176.43 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $168.97 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $168.72 | 2022-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $144.51 | 2019-2023 | Farxiga |
| Heartflow, INC. | $96.70 | 2025 | |
| Amgen INC. | $71.50 | 2019-2023 | Repatha |
| Philips North America LLC | $67.39 | 2023-2025 | Ecc Solutions |
| Idorsia Pharmaceuticals US INC | $60.41 | 2024 | Tryvio |
| Merck Sharp & Dohme LLC | $49.88 | 2022-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.76 | 2022-2023 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $42.37 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $40.48 | 2023 | Arcalyst |
| Teleflex LLC | $40.21 | 2023-2025 | Guideliner |
| Janssen Pharmaceuticals, INC | $39.06 | 2020-2023 | Xarelto |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $35.49 | 2025 | |
| Abbott Laboratories | $29.01 | 2025 | Coroflow |
| Lexicon Pharmaceuticals, INC. | $28.47 | 2023-2024 | Inpefa |
| Inari Medical, INC. | $26.10 | 2022 | |
| Lantheus Medical Imaging, INC. | $22.60 | 2022 | |
| Bridgebio Pharma, INC. | $21.30 | 2025 | Attruby |
| Medtronic, INC. | $21.21 | 2023 | Corevalve Evolut R |
| Irhythm Technologies, INC. | $17.68 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $17.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.